A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM PRODIGE 63 GERCOR D17-01 study)
ANNÉE
2019
AUTEURS
Neuzillet C, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D
CONGRÈS/REVUE
ASCO
LIEN PUBLICATIONS ASSOCIÉES